

Mark B. Bezilla Vice President - Nuclear 419-321-7676 Fax: 419-321-7582

Docket No. 50-346

License Number NPF-3

Serial Number 3056

August 13, 2004

United States Nuclear Regulatory Commission Document Control Desk Washington, DC 20555-0001

Subject: Revision to Commitments Related to Generic Letter 2003-01, "Control Room

Habitability" (TAC No. MB9796)

Ladies and Gentlemen:

By letter dated August 11, 2003 (Serial Number 2974), the FirstEnergy Nuclear Operating Company (FENOC) submitted a 60-day response to NRC Generic Letter 2003-01 for the Davis-Besse Nuclear Power Station (DBNPS). In its response, FENOC committed to take several actions. FENOC is revising the due dates for completion of some of these commitments. The revised due dates reflect performance of integrated tracer gas testing in 2005 rather than 2004. This change in schedule is based, in part, upon the desire to develop an alternate source term analysis prior to testing. The affected commitments and revised due dates are identified in the enclosure to this letter.

If you have questions or require additional information, please contact Mr. Gregory A. Dunn, Manager - Regulatory Affairs, at (419) 321-8450.

Very truly yours,

MAR

Enclosure

cc: J. L. Caldwell, Regional Administrator, NRC Region III

J. B. Hopkins, NRC/NRR Senior Project Manager

C. S. Thomas, NRC Region III, DB-1 Senior Resident Inspector Utility Radiological Safety Board

A102

Enclosure

COMMITMENT LIST

The following list identifies those actions committed to by the Davis-Besse Nuclear Power Station (DBNPS) in this document. Any other actions discussed in the submittal represent intended or planned actions by the DBNPS. They are described only for information and are not regulatory commitments. Please notify the Manager – Regulatory Affairs (419-321-8450) at the DBNPS of any questions regarding this document or any associated regulatory commitments.

COMMITMENT	DUE DATE
The requested confirmation that the Control Room meets the applicable regulatory requirements and the DBNPS design and licensing basis will be provided in a final response to this Generic Letter.	Within three months after the above reviews, walkdowns, analyses and tests are completed. (No later than March 31, 2006)
The conclusions of the confirmatory reviews for this item will be provided along with the overall final response to the generic letter.	Within three months after the above reviews, walkdowns, analyses and tests are completed. (No later than March 31, 2006)
A review of dose calculations for DBAs will be conducted.	December 31, 2005
The need for surveillance requirement changes will be evaluated after the completion of analyses and testing.	December 31, 2005